Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing Market Size, Share & Trends by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028

Report Code: PH 7263 Apr, 2023, by marketsandmarkets.com

Pharmaceutical Contract Manufacturing Market Size, Share & Trends

The size of global pharmaceutical contract manufacturing market in terms of revenue was estimated to be worth $176.5 billion in 2023 and is poised to reach $258.3 billion by 2028, growing at a CAGR of 7.9% from 2023 to 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

Various elements such as rising research activities and funding investments for generic medicines, technological advancements in CDMOs, the high cost of in-house drug development, and the regulatory filling support provided by CDMOs, are driving the market growth.

Pharmaceutical Contract Manufacturing Market Trends

Pharmaceutical Contract Manufacturing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing Market Dynamics

DRIVER: High cost of In-House drug development is likely to propel the market growth

Drug discovery and development is highly expensive and time-consuming process for small and medium-sized pharmaceutical companies. However, pharmaceutical companies opt for a cheaper and efficient solution, i.e., to outsource their drug development processes to contract development and research organizations.

Also, drug development requires following stringent US FDA guidelines and maintaining quality and standards while developing formulations. This increases the in-house drug development and manufacturing cost of the formulation. Thus, the continuously increasing drug development costs, influenced by the costs of discovery & pre-clinical development, clinical development, capital, shortage of funds, and high failure rates for drugs tested on human subjects, pushed pharmaceutical companies to outsource their drug development processes to contract development and manufacturing organizations.

RESTRAINT: Varying regulatory requirements across regions

Noncompliance of guidelines and regulations by the respective authority and inferior quality of manufactured drugs brings serious consequences to the business and the brand name. Hence, compliance with regulatory guidelines is paramount in the pharmaceutical industry. For CDMOs, the drug substance/formulation manufactured on a contract basis is sold under the contractor’s brand. That requires large amounts of data to be submitted to the regulatory authority as the drug moves through phases of development and clinical trials. Hence, the handling of the data and submissions of different formulations across various countries becomes difficult for CDMOs and increases the risk of errors in regulatory filings. This factor will likely hamper the market growth of pharmaceutical CDMOs in the coming years.

OPPORTUNITY: Emerging markets

Emerging countries are bioprocess outsourcing hubs due to their cost advantages and workforce. Moreover, the increasing interest of pharmaceutical companies in drug discovery outsourcing due to the ever-increasing demand for vaccines, drying antibiotics pipelines, and rising R&D costs further fuel the growth of pharmaceutical contract development and manufacturing services in emerging markets. Likewise, advanced manufacturing technologies and the low manufacturing cost, low labour cost offered by emerging countries are supporting market players to invest in developing markets like Asia Pacific during the forecast period.  Due to these factors, emerging markets such as India and China are expected to provide significant opportunities for the growth of the pharmaceutical contract manufacturing and development market in the coming years.

CHALLENGE: Introduction of Serialization

Serialization is the process of allowing an individual identity by using a predetermined coding type for each service/product item, giving it a separate identity for tracking and tracing its location in the supply chain. As counterfeiting has become a concern for regulatory authorities and manufacturers globally. Thus, where contract manufacturing is concerned, CDMOs worldwide must execute a robust pharma serialization solution. This requires significant capital investment for software, hardware, personnel training, implementation across their sites, equipped production lines, and skilled staff. Becoming a tough challenge for a CDMO to look after. Hence, it can be considered as a challenge for pharmaceutical contract development and the manufacturing market.

Pharmaceutical Contract Manufacturing Market – Ecosystem

Pharmaceutical Contract Manufacturing Market Ecosystem

The pharmaceutical manufacturing services segment dominated the pharmaceutical contract manufacturing industry in 2022.

Based on service, the pharmaceutical contract manufacturing market is broadly segmented into pharmaceutical manufacturing service, drug development service, and biologic manufacturing service. In 2022, pharmaceutical manufacturing services accounted for the dominant share, segment's large share can be attributed to factors such as the increasing biopharmaceuticals and pharmaceutical markets across the globe, and rising demand for biologics and biosimilars in the region. Furthermore,

Key Market Players are investing in drug discovery and development in the market is likely to spur the growth of the segment.

The big pharmaceutical companies segment of the pharmaceutical contract manufacturing industry is expected to grow at the highest CAGR during the forecast period.

Based on end user, the pharmaceutical contract manufacturing market is segmented into big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). The big pharmaceutical companies segment is expected to register the highest CAGR during the forecast period. Increased investment in the development of cell and gene therapies, increased number of biologics currently under pipeline studies, and the rising demand for targeted drug therapies are some of the major factor anticipated to drive the growth of market.

North America dominated the pharmaceutical contract manufacturing industry in 2022.

Pharmaceutical Contract Manufacturing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the pharmaceutical contract manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2021, North America accounted for the largest share in the market, followed by Europe and the Asia Pacific. The large share of the North American market is owing to various factors such presence of a large number of pharmaceutical companies and the growing demand for generics. Increased research funding for pharmaceutical contract development and manufacturing is furthermore driving market growth in North America.

Key players operating in the pharmaceutical contract manufacturing market are Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), and WuXi AppTec (China).

Scope of the Pharmaceutical Contract Manufacturing Industry

Report Metric

Details

Market Revenue Size in 2023

$176.5 billion

Projected Revenue Size by 2028

$258.3 billion

Industry Growth Rate

Poised to Grow at a CAGR of 7.9%

Market Driver

High cost of In-House drug development is likely to propel the market growth

Market Opportunity

Emerging Markets

This report categorizes the pharmaceutical contract manufacturing market to forecast revenue and analyze trends in each of the following submarkets:

By Service
  • Pharmaceutical Manufacturing Services
  • Pharmaceutical API Manufacturing Services
  • Pharmaceutical FDF Manufacturing Services
  • Drug Development Services
  • Biologic Manufacturing Services
  • Biologic API Manufacturing Services
  • Biologic FDF Manufacturing Services
By End User
  • Big Pharmaceutical Companies
  • Small & Mid Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End Users (Academic Institutes, Small CDMOs, and CROs)
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments of Pharmaceutical Contract Manufacturing Industry

  • In September 2022, Lonza Group collaborated with Touchlight, a biotechnology company. Lonza expanded its end-to-end offering for mRNA manufacturing with an additional source of DNA.
  • In February 2022, Thermo Fisher Scientific collaborated with Moderna, Inc. for the large-scale manufacturing of Moderna’s COVID-19 vaccine, Spikevax, and other investigational mRNA medicines in its pipeline.
  • In January 2023, Catalent supported the manufacturing of Sarepta’s most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001), to treat Duchenne muscular dystrophy.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 36)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 STAKEHOLDERS 
    1.7 LIMITATIONS 
    1.8 SUMMARY OF CHANGES 
    1.9 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER)
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 
          FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: CAGR PROJECTIONS, 2023–2028
          FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 IMPACT ANALYSIS OF RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 52)
    FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
    FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT MAMARKET
 
4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW 
          FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET, BY SERVICE & COUNTRY (2022) 
          FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY SERVICE, 2023 VS. 2028 (USD BILLION) 
          FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028
    4.4 MARKET SHARE, BY END USER, 2022 
          FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 60)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increased investment in precision medicines
                    5.2.1.2 Patent expiry & increasing demand for generic drugs
                                TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR
                    5.2.1.3 High cost of in-house drug development
                                FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
                    5.2.1.4 Investments in advanced manufacturing technologies by CDMOs
           5.2.2 RESTRAINTS
                    5.2.2.1 Varying regulatory requirements across regions
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising demand for cell & gene therapy
                                TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022
                    5.2.3.2 Growing inclination toward one-stop-shop model
                    5.2.3.3 Market expansion in emerging countries
                    5.2.3.4 Growth of nuclear medicine
           5.2.4 CHALLENGES
                    5.2.4.1 Introduction of serialization
                    5.2.4.2 Intellectual property risk
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE
    5.4 ECOSYSTEM ANALYSIS 
          FIGURE 23 ECOSYSTEM ANALYSIS: MARKET
          TABLE 7 MARKET: ROLE IN ECOSYSTEM
    5.5 TECHNOLOGY ANALYSIS 
    5.6 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 THREAT OF SUBSTITUTES
           5.6.3 BARGAINING POWER OF SUPPLIERS
           5.6.4 BARGAINING POWER OF BUYERS
           5.6.5 INTENSITY OF COMPETITIVE RIVALRY
    5.7 REGULATORY ANALYSIS 
          TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES
    5.8 KEY CONFERENCES & EVENTS, 2022–2023 
          TABLE 14 MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023
    5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
           5.9.2 BUYING CRITERIA
                    FIGURE 25 KEY BUYING CRITERIA FOR END USERS
    5.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 
          FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR MARKET
    5.11 ANDA APPROVALS 
          FIGURE 27 ANDA APPROVALS, 2018–2022
          FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022
          FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM
 
6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE (Page No. - 81)
    6.1 INTRODUCTION 
          TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY SERVICE, 2021–2028 (USD BILLION)
    6.2 PHARMACEUTICAL MANUFACTURING SERVICES 
          TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
          TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
           6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
                    6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing
                                TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
           6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
                    TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                    TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.1 Parenteral/Injectable manufacturing services
                               6.2.2.1.1 Increasing investments in drug development to support market growth
                                              TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                              TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.2 Tablet manufacturing services
                               6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth
                                              TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                              TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.3 Capsule manufacturing services
                               6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing
                                              TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                              TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.4 Oral liquid manufacturing services
                               6.2.2.4.1 Complexities in handling liquids to promote outsourcing
                                              TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                              TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.5 Semi-solid manufacturing services
                               6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing
                                              TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                              TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                              TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    6.2.2.6 Other FDF manufacturing services
                                TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.3 DRUG DEVELOPMENT SERVICES 
           6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING
                    TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                    TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.4 BIOLOGIC MANUFACTURING SERVICES 
          TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
          TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
           6.4.1 BIOLOGIC API MANUFACTURING SERVICES
                    6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector
                                TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
           6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES
                    6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing
                                TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
                                TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
                                TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
 
7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER (Page No. - )
    7.1 INTRODUCTION 
          TABLE 84 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
    7.2 BIG PHARMACEUTICAL COMPANIES 
           7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH
                    TABLE 85 MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 86 NORTH AMERICA: MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 87 EUROPE: MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 88 ASIA PACIFIC: MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 89 LATIN AMERICA: MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
    7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 
           7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET
                    TABLE 90 MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION)
                    TABLE 91 NORTH AMERICA: MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 92 EUROPE: MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 93 ASIA PACIFIC: MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 94 LATIN AMERICA: MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
    7.4 GENERIC PHARMACEUTICAL COMPANIES 
           7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET
                    TABLE 95 MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION)
                    TABLE 96 NORTH AMERICA: MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 97 EUROPE: MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 98 ASIA PACIFIC: MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
                    TABLE 99 LATIN AMERICA: MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
    7.5 OTHER END USERS 
          TABLE 100 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD BILLION)
          TABLE 101 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 102 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 103 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 104 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
 
8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION (Page No. - 133)
    8.1 INTRODUCTION 
          TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY REGION, 2021–2028 (USD BILLION)
    8.2 NORTH AMERICA 
          FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
          TABLE 106 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 107 NORTH AMERICA: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
          TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.2.1 US
                    8.2.1.1 US to dominate North American market
                                TABLE 112 US: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 116 US: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.2.2 CANADA
                    8.2.2.1 Rising government funding and support to propel market
                                TABLE 117 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 121 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.2.3 NORTH AMERICA: RECESSION IMPACT
    8.3 EUROPE 
          TABLE 122 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 123 EUROPE: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
          TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 127 EUROPE: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.3.1 GERMANY
                    8.3.1.1 Germany to hold largest share throughout forecast period
                                TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.3.2 UK
                    8.3.2.1 Rising investments in drug development to favor market growth
                                TABLE 133 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 137 UK: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.3.3 FRANCE
                    8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market
                                TABLE 138 FRANCE: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.3.4 ITALY
                    8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth
                                TABLE 143 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 147 ITALY: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.3.5 SWITZERLAND
                    8.3.5.1 Growing pharmaceutical industry to support growth
                                TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.3.6 POLAND
                    8.3.6.1 Increasing support for life science R&D to propel market
                                TABLE 153 POLAND: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 157 POLAND: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.3.7 SPAIN
                    8.3.7.1 Rising R&D expenditure to boost market
                                TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.3.8 REST OF EUROPE
                    TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                    TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 167 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.3.9 EUROPE: RECESSION IMPACT
    8.4 ASIA PACIFIC 
          FIGURE 31 ASIA PACIFIC: MARKET SNAPSHOT
          TABLE 168 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 169 ASIA PACIFIC: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
          TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.4.1 CHINA
                    8.4.1.1 China to hold largest share of Asia Pacific market
                                TABLE 174 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 178 CHINA: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.4.2 INDIA
                    8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth
                                TABLE 179 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 183 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.4.3 JAPAN
                    8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing
                                TABLE 184 JAPAN: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 188 JAPAN: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.4.4 SOUTH KOREA
                    8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
                                TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.4.5 REST OF ASIA PACIFIC
                    TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                    TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 198 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.4.6 ASIA PACIFIC: RECESSION IMPACT
    8.5 LATIN AMERICA 
          TABLE 199 LATIN AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
          TABLE 200 LATIN AMERICA: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
          TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
          TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.5.1 BRAZIL
                    8.5.1.1 Growing pharmaceutical industry to drive market
                                TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                                TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                                TABLE 209 BRAZIL: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.5.2 REST OF LATIN AMERICA
                    TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                    TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY, BY END USER, 2021–2028 (USD BILLION)
           8.5.3 LATIN AMERICA: RECESSION IMPACT
    8.6 MIDDLE EAST & AFRICA 
           8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH
                    TABLE 215 MIDDLE EAST & AFRICA: MARKET, BY SERVICE, 2021–2028 (USD BILLION)
                    TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
                    TABLE 219 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD BILLION)
           8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
9 COMPETITIVE LANDSCAPE (Page No. - 204)
    9.1 OVERVIEW 
    9.2 KEY PLAYER STRATEGIES 
          TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020–2023
    9.3 REVENUE SHARE ANALYSIS 
          FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022
    9.4 MARKET SHARE ANALYSIS 
          FIGURE 33 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY SHARE ANALYSIS, BY KEY PLAYER, 2022
          TABLE 221 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
                    FIGURE 34 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: COMPANY EVALUATION QUADRANT, 2022
    9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
           9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
                    TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN MARKET
           9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES)
                    TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN MARKET
           9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                    TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MARKET
    9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022) 
           9.7.1 PROGRESSIVE COMPANIES
           9.7.2 STARTING BLOCKS
           9.7.3 RESPONSIVE COMPANIES
           9.7.4 DYNAMIC COMPANIES
                    FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
    9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 
          TABLE 225 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: DETAILED LIST OF KEY START-UP/SME PLAYERS
          TABLE 226 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    9.9 COMPETITIVE SCENARIO AND TRENDS 
           9.9.1 SERVICE LAUNCHES
                    TABLE 227 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023
           9.9.2 DEALS
                    TABLE 228 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: DEALS, JANUARY 2020–MARCH 2023
           9.9.3 OTHER DEVELOPMENTS
                    TABLE 229 PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020–MARCH 2023
 
10 COMPANY PROFILES (Page No. - 219)
     10.1 KEY MARKET PLAYERS 
(Business Overview, Services Offered, Recent Developments, and MnM View)*
             10.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             10.1.2 CATALENT, INC.
                        TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW
                        FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022)
             10.1.3 LONZA GROUP
                        TABLE 232 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022)
             10.1.4 ABBVIE, INC.
                        TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW
                        FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022)
             10.1.5 WUXI APPTEC
                        TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW
                        FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022)
             10.1.6 EVONIK INDUSTRIES AG
                        TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW
                        FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022)
             10.1.7 SAMSUNG BIOLOGICS
                        TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
                        FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
             10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
                        FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
             10.1.9 SIEGFRIED HOLDING AG
                        TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
                        FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022)
             10.1.10 FUJIFILM HOLDINGS CORPORATION
                        TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
             10.1.11 EUROFINS SCIENTIFIC
                        TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             10.1.12 PIRAMAL PHARMA SOLUTIONS
                        TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
                        FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
             10.1.13 RECIPHARM AB
                        TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW
             10.1.14 ALMAC GROUP
                        TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW
             10.1.15 VETTER PHARMA
                        TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     10.2 OTHER PLAYERS 
             10.2.1 DELPHARM HOLDINGS
             10.2.2 YUHAN CORPORATION
             10.2.3 CURIA GLOBAL, INC.
             10.2.4 CHARLES RIVER LABORATORIES
             10.2.5 LANNETT COMPANY, INC.
             10.2.6 CAMBREX CORPORATION
             10.2.7 FAMAR HEALTHCARE SERVICES
             10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED)
             10.2.9 SAI LIFE SCIENCES LIMITED
             10.2.10 PCI PHARMA SERVICES
 
11 APPENDIX (Page No. - 282)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the pharmaceutical contract manufacturing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the market. The secondary sources referred to for this research study include publications from government and private sources such as the Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), US Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), National Center for Biotechnology Information, Global Cancer Observatory, World Health Organization (WHO), World Bank, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Journals, Expert Interviews, MarketsandMarkets Analysis. Secondary data was collected and analyzed to arrive at the overall size of the global pharmaceutical contract manufacturing market, which was then validated by primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Pharmaceutical Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down approach was used to estimate and validate the total size of the pharmaceutical contract manufacturing market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the pharmaceutical contract development and manufacturing business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Pharmaceutical Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global market size: Top-Down Approach

Pharmaceutical Contract Manufacturing Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmaceutical contract development and manufacturing organizations (CDMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CDMOs provide manufacturing services for both active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs).

Different aspects of contract manufacturing, such as drug discovery, preclinical development, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this market.

Key Stakeholders

  • Pharmaceutical distributors and suppliers
  • Corporate entities
  • Biotechnology and pharmaceutical companies
  • Government agencies
  • Academic and research institutions
  • Research Institutes and Academic Centers
  • Business Research and Consulting Service Providers
  • Venture Capitalists
  • Contract Research Organizations and Contract Development Manufacturing Organizations

Report Objectives

  • To define, describe, and forecast the global pharmaceutical contract manufacturing market based on the service, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as service launched, acquisitions, expansions, agreements, collaborations, and R&D activities in the pharmaceutical contract manufacturing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the Rest of Europe market into respective countries
  • Further breakdown of the Rest of Asia Pacific market into respective countries
  • Further breakdown of the Rest of Latin America market into respective countries

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 7263
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback